QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 truist-securities-reiterates-buy-on-terns-pharma-raises-price-target-to-28

Truist Securities analyst Srikripa Devarakonda reiterates Terns Pharma (NASDAQ:TERN) with a Buy and raises the price target ...

 bmo-capital-maintains-outperform-on-terns-pharma-raises-price-target-to-22

BMO Capital analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Outperform and raises the price target from $15...

 barclays-maintains-overweight-on-terns-pharma-raises-price-target-to-27

Barclays analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Overweight and raises the price target from $14 to...

 hc-wainwright--co-upgrades-terns-pharma-to-buy-announces-20-price-target

HC Wainwright & Co. analyst Andres Y. Maldonado upgrades Terns Pharma (NASDAQ:TERN) from Neutral to Buy and announces $2...

 william-blair-upgrades-terns-pharma-to-outperform

William Blair analyst Andy Hsieh upgrades Terns Pharma (NASDAQ:TERN) from Market Perform to Outperform.

 terns-pharmaceuticals-leukemia-drug-seen-as-potential-disruptor-in-cml-treatment-landscape-analyst-upgrades

Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the sto...

 terns-pharmaceuticals-announces-tern-701-shows-64-mmr-at-24-weeks-in-heavily-pretreated-cml-patients-to-present-data-at-ash-2025

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient populationEncouraging safe...

 jmp-securities-maintains-market-outperform-on-terns-pharma-lowers-price-target-to-15

JMP Securities analyst Silvan Tuerkcan maintains Terns Pharma (NASDAQ:TERN) with a Market Outperform and lowers the price ta...

 why-is-terns-pharmaceuticals-stock-trading-lower-after-obesity-trial-data

Terns Pharmaceuticals announces 12-week Phase 2 results for oral obesity drug TERN-601, showing up to 4.6% weight loss but repo...

 barclays-maintains-overweight-on-terns-pharma-lowers-price-target-to-14

Barclays analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Overweight and lowers the price target from $15 to...

 terns-pharma-reports-topline-12-week-results-from-phase-2-trial-of-tern-601-once-daily-oral-glp-1-receptor-agonist-as-potential-treatment-for-obesity

Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse eventsAsymptomatic,...

 truist-securities-initiates-coverage-on-terns-pharma-with-buy-rating-announces-price-target-of-20

Truist Securities analyst Srikripa Devarakonda initiates coverage on Terns Pharma (NASDAQ:TERN) with a Buy rating and announ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION